31 March, 2016
Chordate Medical has been granted a US patent covering a device for detecting rhinitis in a human subject by a pressure sensing system and method. We continue to strengthen our global IP protection of the technology that forms the base for current and future products. Our IP insurance enable us to protect our patents from infringement.
If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.
Press releases
For questions about Chordate's share price or other investment-related topics, please see if the answer is here.
For questions about the medical effects of the K.O.S treatment, please see if the answer is here.
To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company's share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.
The information is handled according to our privacy policy.
This website uses cookies to give you the best and most relevant user experience. Using this website means you consent to the use of cookies. Find out more about cookies on our website.